XIENCE ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM
Report
- Report Number
- 2024168-2016-02012
- Event Type
- Injury
- Date Received
- March 28, 2016
- Date of Event
- December 26, 2014
- Report Date
- March 28, 2016
- Manufacturer
- AV-TEMECULA-CT
- Product Code
- NIQ
- PMA / PMN Number
- P110019
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- OH, US
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
(B)(4). LAB DATA: ON (B)(6) 2014 (06:34): CK=52 U/L, NORMAL UPPER LIMIT 200. ON (B)(6) 2014 (06:34): CK-MB=5.0 NG/ML, NORMAL UPPER LIMIT 5.0. CONCOMITANT PRODUCTS: DILATATION CATHETER: EMERGE 2.5X8, NC EUPHORA 3.75X8. (B)(4). THERE WAS NO REPORTED DEVICE MALFUNCTION AND THE PRODUCT WAS NOT RETURNED. A REVIEW OF THE LOT HISTORY RECORD IDENTIFIED NO MANUFACTURING NONCONFORMITIES ISSUED TO THE REPORTED LOT THAT WOULD HAVE CONTRIBUTED TO THIS EVENT. DISSECTION IS LISTED IN THE XIENCE ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEMS INSTRUCTIONS FOR USE AS A KNOWN PATIENT EFFECT OF CORONARY STENTING PROCEDURES. A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECT AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED AND THERE IS NO INDICATION OF A PRODUCT QUALITY ISSUE WITH RESPECT TO MANUFACTURE, DESIGN OR LABELING.
IT WAS REPORTED THAT ON (B)(6) 2014, A 3.5X15MM XIENCE ALPINE STENT WAS SUCCESSFULLY IMPLANTED IN THE DISTAL CIRCUMFLEX (CX) CORONARY ARTERY. FOLLOWING, A HAZY AREA IN THE MID CX WAS NOTED AND WAS TREATED WITH A 3.5X12MM XIENCE ALPINE STENT, RESOLVING THE DISSECTION. ANOTHER 3.5X12MM XIENCE ALPINE STENT WAS SUCCESSFULLY IMPLANTED IN THE PROXIMAL CX CORONARY ARTERY LESION. ON (B)(6) 2014, THE PATIENT WAS DISCHARGED HOME. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 186523 | XIENCE ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM | DRUG ELUTING CORONARY STENT SYSTEM | NIQ | AV-TEMECULA-CT | 4070841 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 56 YR | Required Intervention |